LncRNA NEAT1 Promotes High Glucose-Induced Mesangial Cell Hypertrophy by Targeting miR-222-3p/CDKN1B Axis

Lin Liao, Jie Chen, Chuanfu Zhang, Yue Guo, Weiwei Liu, Wenrui Liu, Lianxiang Duan, Ziyang Liu, Jing Hu, Jianrao LuFrontiers in Molecular Biosciences 2021 · DOI

TL;DR

This study uncovers a novel molecular pathway where the long non-coding RNA (lncRNA) NEAT1 drives high glucose-induced mesangial cell hypertrophy in diabetic nephropathy. NEAT1 acts as a "molecular sponge" for miR-222-3p, leading to increased expression of CDKN1B, a key regulator of cell cycle arrest and hypertrophy. This discovery sheds light on a new regulatory mechanism in diabetic kidney disease and suggests potential therapeutic targets.

What Problem Does This Paper Address?

Diabetic nephropathy, a severe complication of diabetes, is characterized by glomerular hypertrophy, an early sign of kidney damage. While it's known that Cyclin-Dependent Kinase inhibitors (like CDKN1B) are involved in this hypertrophy, the upstream regulators controlling CDKN1B's expression in this context have remained largely unknown. This paper aims to elucidate this missing link by investigating the role of long non-coding RNAs (lncRNAs), specifically NEAT1, in the development of high glucose-induced mesangial cell hypertrophy.

Methods

The researchers employed a multi-pronged approach to dissect the NEAT1-mediated pathway:

  • Quantitative PCR (qPCR): Used to measure the expression levels of NEAT1 and miR-222-3p in both patient samples and cell cultures under different glucose conditions.
  • Flow Cytometry: Employed to analyze cell cycle progression, specifically identifying changes in G0-G1, S, and G2/M phases, which are indicative of proliferation and arrest.
  • Western Blotting: Utilized to detect and quantify protein levels, particularly for CDKN1B, to assess its expression in response to NEAT1 manipulation and high glucose.
  • RNA Immunoprecipitation (RIP) and RNA Pull-Down Assays: These techniques were crucial for demonstrating the direct interaction between NEAT1 and miR-222-3p, confirming NEAT1's role as a competing endogenous RNA (ceRNA).
  • Luciferase Reporter Assays: Used to validate the binding interactions between NEAT1 and miR-222-3p, and between miR-222-3p and the 3' UTR of CDKN1B mRNA. They also investigated the transcriptional regulation of NEAT1 by STAT3.
  • Chromatin Immunoprecipitation (ChIP) Assay: Employed to confirm the binding of STAT3 to the NEAT1 promoter, providing evidence for STAT3's role in NEAT1 transcription.
  • Cellular Hypertrophy Assays: Measured by assessing the ratio of total cellular protein to cell number, and also by quantifying protein synthesis using [35S]-methionine incorporation.
  • Gene Knockdown and Overexpression: Short hairpin RNA (shRNA) was used to reduce NEAT1 expression, while lentiviral vectors were used to overexpress NEAT1 and introduce miR-222-3p mimics or inhibitors. siRNA was used to knock down CDKN1B.

Datasets

The study utilized:

  • Human Renal Tissues: Samples from patients diagnosed with diabetic nephropathy and adjacent normal renal tissue from patients with renal carcinoma were used for initial expression analysis of NEAT1 and miR-222-3p.
  • Human Mesangial Cells: These primary cells were cultured in vitro and subjected to various experimental manipulations (high glucose, gene knockdown/overexpression, miRNA treatment) to study the molecular mechanisms.

No new benchmarks were introduced; standard techniques were applied to analyze the biological samples and cell cultures.

Key Insights and Ideas

  • NEAT1 as a "Molecular Sponge": The most striking finding is NEAT1's function as a ceRNA, directly binding to miR-222-3p. This interaction prevents miR-222-3p from binding to its target, CDKN1B mRNA. This is a critical insight into how lncRNAs can indirectly regulate protein expression.
  • The miR-222-3p/CDKN1B Axis: The paper clearly establishes miR-222-3p as a negative regulator of CDKN1B. When miR-222-3p levels are low (due to NEAT1's action), CDKN1B expression increases, leading to cell cycle arrest and hypertrophy.
  • STAT3 as an Upstream Regulator of NEAT1: The study identifies STAT3, a transcription factor activated by high glucose, as a key regulator of NEAT1 transcription. This links the initial hyperglycemic insult to the downstream lncRNA-mediated pathway.
  • A Novel Pathway for Hypertrophy: The research proposes a comprehensive pathway: High Glucose → STAT3 activation → NEAT1 transcription → NEAT1 sequesters miR-222-3p → Increased CDKN1B expression → Mesangial cell hypertrophy. This provides a more complete picture of the molecular events driving this pathological process.

Key Results

  • Elevated NEAT1 in Diabetic Nephropathy: NEAT1 expression was significantly higher in renal tissues of patients with diabetic nephropathy compared to controls.
  • HG Induces NEAT1 and Hypertrophy: High glucose treatment in human mesangial cells led to increased NEAT1 expression and promoted cellular hypertrophy, evidenced by increased protein synthesis and total protein content per cell.
  • NEAT1 Knockdown Reverses HG Effects: Knocking down NEAT1 in high glucose conditions reduced mesangial cell hypertrophy, decreased protein synthesis, and shifted the cell cycle towards proliferation (fewer cells in G0-G1).
  • miR-222-3p is Negatively Regulated by NEAT1: NEAT1 directly binds to miR-222-3p, and this interaction was confirmed through multiple assays. miR-222-3p expression was lower in diabetic nephropathy patients and negatively correlated with NEAT1 levels.
  • miR-222-3p Inhibitor Mimics NEAT1 Effects: Inhibiting miR-222-3p led to increased CDKN1B expression, cell cycle arrest in G0-G1, and enhanced hypertrophy, mirroring the effects of NEAT1.
  • STAT3 Activates NEAT1 Transcription: Inhibition of JAK/STAT signaling (using AG490) reduced NEAT1 expression under high glucose conditions. ChIP assays confirmed STAT3 binding to the NEAT1 promoter.
  • CDKN1B is a Target of miR-222-3p: miR-222-3p directly targets the 3' UTR of CDKN1B mRNA, and its inhibition led to increased CDKN1B expression.
  • CDKN1B Knockdown Reverses NEAT1/miR-222-3p Effects: Knocking down CDKN1B reversed the hypertrophic effects induced by NEAT1 overexpression or miR-222-3p inhibition, highlighting CDKN1B's central role.

Limitations and Future Work

  • In vivo validation: While the study provides strong in vitro evidence and uses patient samples, further validation in animal models of diabetic nephropathy would strengthen the findings.
  • Broader role of STAT3: The study focuses on STAT3's role in NEAT1 transcription. Investigating STAT3's broader impact on other components of this pathway or its role in other aspects of diabetic nephropathy (e.g., inflammation, fibrosis) could be valuable.
  • Therapeutic potential: The authors suggest that targeting any of the players in this pathway (STAT3, NEAT1, miR-222-3p, or CDKN1B) could offer new therapeutic opportunities for HG-induced hypertrophy. Future work could explore the efficacy and safety of such interventions.
  • Context-specific roles of NEAT1 and miR-222-3p: The paper notes that miR-222-3p has been implicated in cancers. Further research could explore if its role in diabetic nephropathy is unique or shares common regulatory mechanisms with other diseases. Similarly, NEAT1's role in immune regulation and other cellular processes warrants further investigation.

Summary updated

Abstract

Glomerular hypertrophy is an early morphological alteration in diabetic nephropathy. Cyclin-Dependent Kinases have been shown to be required for high glucose (HG)-induced hypertrophy; however, the upstream regulators of CDKN1B in glomerular hypertrophy remain unclear. Herein we describe a novel pathway in which Long noncoding RNA (lncRNA) NEAT1 regulates the progression of mesangial cell hypertrophy via a competing endogenous RNA (ceRNA) mechanism. Real-time PCR was performed to detect the relative NEAT1 and miR-222-3p expressions and further confirmed the relationship between NEAT1 and miR-222-3p. Cell cycle was evaluated by flow cytometry. The related mechanisms were explored by Western blot, RNA immunoprecipitation and chromatin immunoprecipitation assay. We show that NEAT1 forms double stranded RNA (dsRNA) with miR-222-3p, thus limiting miR-222-3p's binding with CDKN1B. This release of CDKN1B mRNA leads to elevated CDKN1B protein expression, resulting in hypertrophy. In addition, we demonstrated that STAT3 which is activated by HG induces the transcription of NEAT1 by binding to its promoter. Our findings underscore an unexpected role of lncRNAs on gene regulation and introduce a new mode of proliferation regulation in mesangial cells.
BibTeX
@inproceedings{liao2021lncrna,
  author = {Lin Liao and Jie Chen and Chuanfu Zhang and Yue Guo and Weiwei Liu and Wenrui Liu and Lianxiang Duan and Ziyang Liu and Jing Hu and Jianrao Lu},
  title = {{LncRNA NEAT1 Promotes High Glucose-Induced Mesangial Cell Hypertrophy by Targeting miR-222-3p/CDKN1B Axis}},
  booktitle = {Frontiers in Molecular Biosciences},
  year = {2021},
  doi = {10.3389/fmolb.2020.627827},
}
Figure